Instinct Bio Stock Slides After Hours: Here's What is Going on With BIOT - Instinct Bio Technical Co (NAS
Instinct Bio (BIOT) shares fell 51.46% to $1.33 Tuesday and dropped another 20.30% in after-hours to $1.06. The Nasdaq-listed biotech completed a business combination with Relativity Acquisition Corp. It entered an indicative term sheet for an equity purchase facility to sell up to $150M of common stock over three years, priced near VWAP less a discount, to fund development and working capital.
How this was made
The 30-second read
Why it matters
BIOT’s after-hours slide appears tied to the disclosed plan to potentially raise up to $150M via an equity purchase facility, which investors may interpret as dilution.
Market read
Traders should focus on dilution expectations and the likelihood/timing of actual share sales under the facility.
What to watch
The term sheet is indicative, not finalized; actual issuance size, discount terms, and regulatory approvals could differ from what the market is currently pricing.
Background
Instinct Bio completed a business combination with Relativity Acquisition Corp. and began trading on Nasdaq under BIOT.
Ticker impact
Instinct Bio disclosed an indicative equity purchase facility to sell up to $150M of common stock, driving dilution concerns after a sharp selloff.
Near-term downside bias with elevated volatility as traders price dilution and financing overhang.
The article’s newest concrete fact is the indicative term sheet for an equity purchase facility with VWAP-minus discount pricing, which typically signals incremental share issuance and dilution risk.
Market effects
Highlights ongoing financing pressure in regenerative medicine and longevity biotech, where equity facilities can weigh on sentiment.
Primarily impacts Nasdaq-listed micro-cap biotech liquidity and risk appetite.
Limited broader global impact; mostly a company-specific dilution/financing overhang signal.
Counterpoint
The facility could extend runway and accelerate development, which may reduce near-term funding risk if execution improves.
Key entities
- companyInstinct Bio
Regenerative medicine and longevity-focused biotech that trades on Nasdaq as BIOT.
- companyRelativity Acquisition Corp.
SPAC counterparty in Instinct Bio’s business combination.
